Innovative new defibrillator offers alternative for regulating heart beat

October 3, 2012

A new ground-breaking technology was recently used at the University of Ottawa Heart Institute (UOHI) where two cardiologists, Dr. David Birnie and Dr. Pablo Nery, implanted a new innovative leadless defibrillator, the subcutaneous implantable cardioverter defibrillator (S-ICD), to a 18 year-old patient. Under Health Canada's special access program, this was only the third time this new type of ICD had been implanted in Canada.

Conventional defibrillators, known as transvenous defibrillators, are implanted with wires, called the leads, that snake through veins into the . When the defibrillator identifies any dangerous heartbeat, it delivers a shock through the wires to return the heart to its normal rhythm and allow it to get back to pumping blood steadily throughout the body.

Not all are suitable for a conventional defibrillator. In some with congenital heart problems, there is no way to advance the leads into the heart through the veins. Also, those wires may pose a danger due to the risk of or infection. Patients often have to undergo a more complex and to attach the leads to the outer layer of the heart muscle in order to benefit from the use of a defibrillator

Conventional ICDs use leads that run from the device through major veins to an anchor point in the heart. These transvenous leads can cause problems in the long term. Despite decades of design improvements, leads can malfunction, break or stop working. Known as lead failure, this results in either inappropriate shocks or lack of proper regulation of the heartbeat. What's worse is that failed leads often must be removed, which poses serious risks to the patient.

What makes the new device special is that it is entirely subcutaneous. No part of it actually touches the heart. Instead, an electrode is implanted just under the skin near the heart. The defibrillator is connected to the , and monitors the heartbeat at all times. If needed, it delivers a shock to the to restore its normal rhythm.

The goal of the subcutaneous ICD is to potentially reduce or eliminate these problems. "The subcutaneous ICD provides effective therapy for patients who are either not eligible for or are at high risk with a traditional ICD. Such patients may now be able to receive protection from a subcutaneous ICD without the risks associated with the standard leads," explained Dr. Nery.

That made the 18-year-old recipient of the S-ICD at the Heart Institute a perfect candidate. "The S-ICD offers advantages for particular patient sub-groups," said Dr. Nery. "This technology is now an alternative for young patients, in part because lead extraction can be avoided down the road."

Another advantage is more aesthetic in nature but, nonetheless, important for young people. A conventional transvenous defibrillator sits on the front on the chest, just under the collarbone, and is easy to see. The S-ICD, in comparison, is implanted to the side, under the patient's arm, and with a much smaller incision than with the transvenous . That, said Dr. Nery, is an important consideration for many patients in terms of body image and quality of life.

Explore further: Computer software monitoring detects implantable cardioverter-defibrillator malfunctions sooner

Related Stories

Computer software monitoring detects implantable cardioverter-defibrillator malfunctions sooner

March 6, 2012
A software monitoring program that tracks implantable cardioverter-defibrillator (ICD) function could detect problems with the devices earlier than current monitoring processes, according to new research in Circulation: Cardiovascular ...

Education, psychological support key for defibrillator patients

September 24, 2012
Improved patient education and ongoing psychological support will help people cope with the psychological distress of having an implanted defibrillator, according to a scientific statement from the American Heart Association.

Recommended for you

Five vascular diseases linked to one common genetic variant

July 27, 2017
Genome-wide association studies have implicated a common genetic variant in chromosome 6p24 in coronary artery disease, as well as four other vascular diseases: migraine headache, cervical artery dissection, fibromuscular ...

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.